Skip to main content

ADVERTISEMENT

precision medicine

Department
10/04/2016
JCP Editors
In the first study to evaluate patient-reported outcomes from the NRG Oncology/RTOG 0415 trial, treatment with hypofractionated radiation therapy offers similar health-related quality of life (HRQoL) outcomes in...
In the first study to evaluate patient-reported outcomes from the NRG Oncology/RTOG 0415 trial, treatment with hypofractionated radiation therapy offers similar health-related quality of life (HRQoL) outcomes in...
In the...
10/04/2016
Journal of Clinical Pathways
Research in Review
09/30/2016
JCP Editors
Patients with rheumatoid arthritis (RA) previously treated to a first-line anti-tumor necrosis factor (TNF) drug who have an inadequate response may experience a better outcome with a non-TNF biologic agent than with...
Patients with rheumatoid arthritis (RA) previously treated to a first-line anti-tumor necrosis factor (TNF) drug who have an inadequate response may experience a better outcome with a non-TNF biologic agent than with...
...
09/30/2016
Journal of Clinical Pathways
Department
09/28/2016
JCP Editors
A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...
A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...
A...
09/28/2016
Journal of Clinical Pathways
Research in Review
09/26/2016
JCP Editors
There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial. Bevacizumab, along with other angiogenesis inhibitors,...
There is no benefit from the addition of bevacizumab to capecitabine in the adjuvant setting for colorectal cancer, according to results from a clinical trial. Bevacizumab, along with other angiogenesis inhibitors,...
There...
09/26/2016
Journal of Clinical Pathways
Research in Review
09/23/2016
JCP Editors
Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...
Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...
...
09/23/2016
Journal of Clinical Pathways
Research in Review
09/21/2016
JCP Editors
New data from a post-hoc analysis of the Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial found no survival difference at 5 years with endosonography or mediastinoscopy...
New data from a post-hoc analysis of the Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial found no survival difference at 5 years with endosonography or mediastinoscopy...
New...
09/21/2016
Journal of Clinical Pathways
Department
09/17/2016
JCP Editors
Richard Schilsky, MD, senior vice president and chief medical officer of the American Society of Clinical Oncology kicked off the inaugural Clinical Pathways Congress with a discussion on the relationship between...
Richard Schilsky, MD, senior vice president and chief medical officer of the American Society of Clinical Oncology kicked off the inaugural Clinical Pathways Congress with a discussion on the relationship between...
...
09/17/2016
Journal of Clinical Pathways
Research in Review
09/17/2016
JCP Editors
Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed. Researchers at Cedars-Sinai have developed a new method to identify which...
Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed. Researchers at Cedars-Sinai have developed a new method to identify which...
...
09/17/2016
Journal of Clinical Pathways
Research in Review
09/14/2016
JCP Editors
A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies, according to a study published in the journal Clinical...
A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies, according to a study published in the journal Clinical...
A...
09/14/2016
Journal of Clinical Pathways
Research in Review
09/12/2016
JCP Editors
Adding a hypoxia-activated prodrug (HAP) to standard care for epidermal growth factor receptor-positive non-small cell lung cancer may help to delay treatment resistance, according to a study published in PLOS...
Adding a hypoxia-activated prodrug (HAP) to standard care for epidermal growth factor receptor-positive non-small cell lung cancer may help to delay treatment resistance, according to a study published in PLOS...
Adding...
09/12/2016
Journal of Clinical Pathways